

Supplemental Table S1. Clinical and Laboratory Data for All Patients (N=304)

	No. of patients	%
All	304	100
Sex		
Male	182	60
Female	122	40
Age, years		
mean (SD)	64 (9)	
>65	137	45
≤65	167	55
ECOG performance status		
0	138	45
1	140	46
2	26	9
Body surface area, m ²		
mean (SD)	1.54 (0.17)	
Prior therapy		
None	281	92
CRT using 5-FU for LAPC	23	8
Clinical Stage*		
IVa	19	6
IVb	285	94
Subsequent-line chemotherapy after gemcitabine		
None	261	86
S-1 alone	24	8
Gemcitabine+S-1	8	3
5-FU	6	2
Others	5	2
Leukocyte, x10 ³ /mm ³		
mean (SD)	6.2 (3.0)	
>6.1 (ULN)	120	39
≤6.1	184	61
Platelet, x10 ⁴ /mm ³		
mean (SD)	22.3 (7.2)	
>13.1	278	91
≤13.1 (LLN)	26	9
Hemoglobin, g/dL		
mean (SD)	11.9 (1.5)	
>11	226	74
≤11	78	26
Albumin, g/dL		
mean (SD)	3.6 (0.4)	
>3.7	122	40
≤3.7 (LLN)	182	60
Creatinine, mg/dL		
mean (SD)	0.68 (0.19)	
>1.1 (ULN)	8	3
≤1.1	296	97
AST, IU/L		
mean (SD)	33 (23)	
>33 (ULN)	93	31
≤33	211	69
ALT, IU/L		
mean (SD)	39 (40)	
>42 (ULN)	81	27
≤42	223	73
ALP, U/L		
mean (SD)	477 (450)	
>360 (ULN)	128	42
≤360	176	58
Tumor response [†]		
Complete response	0	0
Partial response	18	6
Stable disease	186	61
Progressive disease	58	19
Not evaluable	42	14

*According to Classification of Pancreatic Carcinoma (Japan Pancreas Society, 2003).

†Evaluated after the first two cycles of gemcitabine monotherapy.

Abbreviations: SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; CRT, chemoradiotherapy; 5-FU, 5-fluorouracil; LAPC, locally advanced pancreatic cancer; ULN, upper limit of normal; LLN, lower limit of normal; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase.